What's in Maruho Co., Ltd.'s pipeline?

Maruho Co., Ltd. has 14 drugs in our index: 1 marketed, 0 filed, 5 in Phase 3, 6 in Phase 2, 2 in Phase 1.

Which companies overlap with Maruho Co., Ltd.'s portfolio?

Top competitors by shared drug class: Aspirus Heart and Vascular Institute-Research and Education, Assistance Publique - Hôpitaux de Paris, B&A Therapeutics, China National Center for Cardiovascular Diseases, Dipexium Pharmaceuticals, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/maruho-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-09 · How we verify

Maruho Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maruho Co., Ltd. pipeline: 1 marketed, 0 filed, 5 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 6 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Mitchga	NEMOLIZUMAB	marketed	Interleukin-31 Receptor alpha Antagonist [EPC]	Interleukin-31 receptor subunit alpha	Immunology
M518101	M518101	phase 3			Dermatology
Vehicle Topical Gel	Vehicle Topical Gel	phase 3
CLS006 Vehicle	CLS006 Vehicle	phase 3			Dermatology
CLS006	CLS006	phase 3			Dermatology
CLS001 (Omiganan)	CLS001 (Omiganan)	phase 3	Antimicrobial peptide	Bacterial cell membrane (lipopolysaccharides and lipoteichoic acids)	Infectious Disease / Dermatology

Therapeutic area mix

Dermatology · 3
Cardiovascular · 1
Immunology · 1
Infectious Disease / Dermatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aspirus Heart and Vascular Institute-Research and Education · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
B&A Therapeutics · 1 shared drug class
China National Center for Cardiovascular Diseases · 1 shared drug class
Dipexium Pharmaceuticals, Inc. · 1 shared drug class
Ferrer Internacional S.A. · 1 shared drug class
Guangzhou Yipinhong Pharmaceutical CO.,LTD · 1 shared drug class
Abeona Therapeutics, Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Maruho Co., Ltd.:

Cite this brief

Drug Landscape (2026). Maruho Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/maruho-co-ltd. Accessed 2026-06-09.